Odapipam
Abandoned D1 receptor antagonist
From Wikipedia, the free encyclopedia
Odapipam (INN; developmental code names NNC 01-0756, NNC-756, NO-756) is a selective D1 receptor antagonist of the benzazepine group which was investigated as a potential antipsychotic but was never marketed.[1][2]
| Clinical data | |
|---|---|
| Other names | NNC 01-0756; NNC-01-0756; NNC-010756; NNC010756; NNC01-0756; NNC-756; NNC756; NNC 0756; NNC0756; NO-756; NO756 |
| Drug class | Dopamine D1 receptor antagonist |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H20ClNO2 |
| Molar mass | 329.82 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
It has more than 5,000-fold selectivity for the dopamine D1 receptor (Ki = 0.17 nM) over the dopamine D2 receptor (Ki = 942 nM).[3] Its affinities for other dopamine receptors, such as the dopamine D5 receptor, were not reported.[3][4] In addition to the dopamine D1 receptor, odapipam showed relatively high affinity for the serotonin 5-HT2 receptor (Ki = 4.5 nM; 26-fold lower than for the D1 receptor).[4]
The drug was first described in the scientific literature by 1988.[4][5]
See also
- Substituted 3-benzazepine
- List of investigational antipsychotics
- Berupipam (NNC 22-0010)
- Ecopipam (SCH-39166)
- NNC 01-0687 (ADX-10061)
- SCH-23390